Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICAIT DC Vaccine (Pancreatic Cancer)
- Development stage
- Unknown
- Lead developer
- ImmunoRestoration
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
ICAIT DC Vaccine (Pancreatic Cancer) is an autologous dendritic cell-based immunotherapy developed by ImmunoRestoration for the treatment of HER-2-expressing pancreatic cancer. Utilizing the company's proprietary ICAIT™ (Immune Cell Activation and Immunotherapy Technology) platform, the vaccine is composed of a patient's own dendritic cells that have been harvested, activated, and pulsed with HER-2 (Human Epidermal Growth Factor Receptor 2) antigens. The mechanism of action involves the presentation of these HER-2 antigens to the patient's T-cells, thereby priming and eliciting a targeted adaptive immune response against tumor cells that overexpress the HER-2 protein. The candidate was positioned to transition from preclinical development into Phase 1 clinical trials in late 2019.
- Other names
- ICAIT dendritic cell vaccine (Pancreatic Cancer)HER-2 pulsed dendritic cell vaccineHER2 pulsed dendritic cell vaccineHER 2 pulsed dendritic cell vaccineImmunoRestoration HER-2 DC vaccineICAIT™ DC Vaccine
Beyond the preview
Go deeper on ICAIT DC Vaccine (Pancreatic Cancer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICAIT DC Vaccine (Pancreatic Cancer).